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Background: The main symptoms of allergic rhinitis (AR) are sneezing, rhinorrhea and nasal obstruction. It was reported that the 
nasal skin temperature after intranasal administration of histamine or grass pollen rose. In patients with AR, the levels of nerve growth 
factor (NGF) and vascular endothelial growth factor (VEGF) have increased in nasal fluids and mucosa.
Objective: The present study were to determine the temperature changes of the nose in rat allergic rhinitis model, and if olopatadine, 
an antiallergic agent with histamine H1 receptor antagonistic action, proved to be effective, were studied the productions of NGF and 
VEGF in nasal lavage fluids (NALF). In the present study, we used ovalbumin (OVA)-sensitized rats as an animal model of nasal allergy 
and examined the effects of olopatadine on the skin temperature of the nose area, and the productions of NGF and VEGF in NALF.
Methods: The temperature changes of the nose area were carried out with thermo tracer in rat passively sensitized with OVA 
antiserum. The numbers of sneezing episodes were counted and, NGF and VEGF levels in NALF were examined using the specific 
ELISA.
Results: In OVA-sensitized rats, the number of sneezing episodes increase and the nasal skin temperature rise were provoked after 
OVA challenge. The levels of NGF and VEGF in NALF also were increased. Olopatadine reduced the increased frequency of sneezing 
and the nasal skin temperature rise. It also inhibited the increased NGF and VEGF productions in NALF.
Conclusion: The nasal skin temperature after OVA challenge rose even in OVA-sensitized rats. These results suggest that the 
suppression of the increased NGF and VEGF levels might partially be involved in the improvement of allergy-like behavior (sneezing 
and nasal skin temperature rise) by the treatment of olopatadine.
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INTRODUCTION
Histamine is one of the  most important mediators in allergy. 
In clinical study, wheal and flare tests by histamine iontophoresis 
stimulations have been intensively demonstrated and, have been 
used to compare antihistaminic effects at the skin level [1, 2]. At 
the nose level, antihistaminic effects have been compared with 
nasal flow by rhinomanometry, nasal secretion and nasal symptom 
score (including: rhinorrhea, nasal itching, sneezing, and nasal 
obstruction) by histamine or allergen challenge [3, 4]. 
Intranasal administration of histamine or grass pollen were 
induced a dose-dependent rise in nasal skin temperature [5]. 
The effects of antihistamines using facial thermography were 
consistent with the results of nasal symptom score and wheal 
and flare. It was reported that facial thermography is an objective, 
noninvasive and sensitive method to study antihistaminic activity 
at the nose level [6].
Symptoms of allergic rhinitis (AR) are sneezing, nasal rubbing, 
nasal congestion and rhinorrhea, caused by the interaction 
between chemical mediators and sensory nerves through 
activation of specific receptors. In the clinical study, nerve growth 
factor (NGF) and neuropeptides, such as substance P, neurokinin 
A, and the calcitonin gene-related peptide, are up-regulated and 
their release in nasal fluids has been demonstrated after allergen or 
hypertonic saline exposure [7-9]. Furthermore, nasal vasodilatation 
and increased vascular permeability are important features of AR. 
Angiogenic factor vascular endothelial growth factor (VEGF) has 
also been shown to increase in the nasal mucosa of patients with 
AR, as a result of the increase in nasal vascular permeability and 
congestion [10]. VEGF participates in nasal mucosa swelling from 
increased blood vessel permeability in an immediate reaction 
of AR [11]. VEGF may therefore play an important role in nasal 
mucosal inflammation in AR.
Olopatadine hydrochloride tablet (Olopatadine; Kyowa Hakko 
Kirin, Japan) is an antiallergic agent with histamine H1 receptor 
antagonistic action, prescribed for patients with signs and 
symptoms of AR, chronic urticaria, eczema dermatitis, prurigo, 
pruritis cutaneous, psoriasis vulgaris and erythema exsudativum 
multiform [12]. Olopatadine ophthalmic solution, which inhibits 
the proinflammatory activity of conjunctival mast cells, is an 
effective therapy for allergic conjunctivitis [13]. Additionally, 
olopatadine nasal spray is a steroid-free prescription nasal spray 
that works quickly to fight the symptoms of seasonal AR [14].
We previously reported that olopatadine reduced nasal allergy 
signs in toluene-2,4-diisocyanate-challenged rats and inhibited 
the increased NGF and VEGF levels in nasal lavage fluids (NALF) 
[15]. 
The purposes of the present study were, first, to determine the 
temperature changes of the nose, in an animal model of nasal 
allergy induced by intranasal challenge with ovalbumin (OVA), and, 
second, if olopatadine proved to be effective, to investigate the 
productions of NGF and VEGF in NALF.
MATERIALS AND METHODS
Animals
Male 6-week-old Wistar rats were purchased from Charles 
River Japan (Japan). Animals were maintained at 19-25°C with 30-
70% of humidity on a 12 h light/dark cycle (light on at 7:00), and 
had free access to commercial pellets and water. Experiments 
were performed in accordance with recommendations of the 
institutional animal care and use committee of the Kyowa Hakko 
Kirin Co., Ltd.
Reagents and drugs
Drugs and reagents used in the study were olopatadine 
hydrochloride (Olopatadine; Kyowa Hakko Kirin, Japan), 
prednisolone (Sigma-Aldrich, USA), albumin (OVA; Sigma-Aldrich, 
USA) and Evans blue (Sigma-Aldrich, USA). Olopatadine was 
dissolved in distilled water. Prednisolone was suspended in 0.5 w/
v% methylcellulose solution.
Sensitization with OVA
OVA was prepared at 400 μg/mL in saline and precipitated 
at a 1:1 ratio with Al(OH)3 (20 mg/mL). Rats were immunized by 
an intraperitoneal injection of 200 μg OVA (1 mL OVA-Al(OH)3 
suspension) at Days 1, 2, 3, and 11, following the sensitization 
procedure of Shimizu et al. [16] (Fig. 1). Heat-killed Bordetella 
pertussis bacilli (10
10 in 0.6 mL saline) were given by a foot pat 
injection on Day 1 as an adjuvant.
Intranasal challenge with OVA
At Days 20 or 21, 25 μL of saline containing 2.5 mg of OVA was 
instilled into both airways of nasal cavity for 2 or 4 consecutive 
days. Sham-challenged rats received 25 μL saline in the same 
manner. Olopatadine (3 and 10 mg/kg/day) and prednisolone (10 
mg/kg/day) were orally administered at a volume of 1 mL/100 g apallergy.org
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body weight before OVA challenge.
Measurements of skin temperature
Temperature and relative humidity were continuously monitored 
and maintained constant at 19-25°C and 30-70% of humidity in 
the room. At Days 21 or 22, the skin temperature of the nose area 
(square centered on animal’s nose) was carried out with thermo 
tracer (TH5100 GP-IB; NEC, Japan) at before and 15 min to 6 h after 
the OVA challenge. The changes in skin temperature were showed 
the difference from the temperatures at before the OVA challenge 
by the average and maximum temperature. 
Observation of nasal symptoms
Rats were placed into an observation cage divided into 
compartments (14 × 20 × 15 cm) for 1 h of habituation. After 
intranasal challenge with OVA, number of sneezing episodes, a 
sign of nasal allergy, was counted in a blinded manner during a 10-
min period just after exposure.
Measurement of NGF and VEGF
At 6 h after the final intranasal challenge, rats were anesthetized 
with sodium pentobarbital. Nasal lavages were done using 
catheter. The catheter with rubber tubing covering the head 
of tube was inserted into the tracheal opening the direction of 
upper airway. Both sides of the nasal cavity were lavaged with PBS 
containing a protease inhibitor and centrifuged. Each supernatant 
was aliquoted and frozen at −35°C. ELISA for NGF (Promega, USA) 
and VEGF (R&D Systems, USA) were conducted according to the 
manufacturer’s instructions. The optical density of each well was 
determined using a microplate reader (THERMOmax™; Molecular 
Devices, USA).
Statistical analysis
Data were presented as means ± SE. The Aspin-Welch test 
or Student’s t-test following the F-test, was used for analysis of 
differences between two groups. Multiple comparisons among 
treatment groups were assessed by one-way analysis of variance, 
followed by the Dunnett’s test or the Steel test. Values of p < 0.05 
were considered statistically significant.
RESULTS 
Effect on temperature of the nose area in OVA-induced rat 
rhinitis model
Skin temperature of the nose area after intranasal challenge 
with OVA was risen (Fig. 2). As shown in Fig. 3A, skin maximum 
temperature of the nose area at 0.25, 2 and 6 h after intranasal 
challenge with OVA was significantly risen compared with saline-
treated animals (p = 0.0324, p = 0.0095, p = 0.0031), respectively. 
Skin mean temperature at 0.25, 0.5, 1, 2, 3 or 6 h after OVA 
challenge was significantly risen compared with saline-treated 
animals (p = 0.0007, p = 0.0044, p = 0.0406, p = 0.0018, p = 0.0179, 
p = 0.0161), respectively (Fig. 3B). Skin minimum temperature of 
the nose area did not change with olopatadine-treated animals 
(data not shown). Olopatadine at 10 mg/kg/day significantly 
suppressed the risen maximum temperature at 0.25, 2, 4 and 6 h 
(p = 0.0268, p = 0.0349, p = 0.0137, p = 0.0028), respectively. On 
Fig. 1. Protocol for ovalbumin (OVA) sensitization and challenge. OVA 
was prepared at 400 μg/mL in physiological saline and precipitated at 
1:1 ratio with Al(OH)3 (20 mg/mL). Rats were sensitized by intraperitoneal 
injections of 200 μg OVA (1 mL OVA-Al(OH)3 suspension) on Days 1, 2, 
3 and 11. Bordetella (B.) pertussis (10
10 organisms in physiological saline) 
were injected into the four footpads on Day 1. Rats were challenged with 
OVA in physiological saline (100 mg/mL, 25 μL × 2) into the bilateral nasal 
cavities using a micropipette for 2 or 4 consecutive days. Drugs were orally 
administered 1 h before each OVA challenge. NALF: nasal lavage fluids.
Fig. 2. Nasal skin temperature change after the last nasal ovalbumin 
(OVA) challenge. The images of thermograph were at 1 h after the OVA 
challenge. The temperature is color coded. A change from blue to red 
indicates an increase in temperature. Olopatadine was orally administered 
1 h before the OVA challenge.
before challenge after challenge olopatadineapallergy.org
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the mean temperature, olopatadine significantly suppressed the 
risen maximum temperature at 2 or 6 h (p = 0.0287, p = 0.0128), 
respectively.
Prednisolone at 10 mg/kg/day significantly suppressed the risen 
maximum temperature at 4 and 6 h (p = 0.0284, p = 0.0008) and 
the risen mean temperature at 6 h (p = 0.0011), respectively.
Effect on sneezing in OVA-induced rat rhinitis model
In OVA-sensitized rats challenged with OVA, there was an 
increase in the number of sneezing episodes compared to saline-
challenged animals (p = 0.0002) (Fig. 4). Olopatadine (3 and 10 
mg/kg/day) significantly suppressed the increased frequency of 
sneezing by 49.3% and 85.0% (p = 0.0016, p < 0.0001), respectively. 
Prednisolone also significantly suppressed the increased number 
of sneezing by 87.1% (p < 0.0001).
Effect of olopatadine on NGF levels in an OVA-induced rat 
rhinitis model
As shown in Fig. 5A, level of NGF in the NALF at 6 h after OVA 
challenge was significantly increased compared to saline-treated 
animals (p = 0.0175, p = 0.0003), respectively. Olopatadine at 10 
mg/kg/day significantly inhibited the increased levels of NGF 
by 85.4% (p = 0.0282), respectively. Prednisolone significantly 
inhibited the increased levels of NGF by 80.9% (p = 0.0420).
Effect of olopatadine on VEGF in an OVA-induced rat rhinitis 
model
As shown in Fig. 5B, level of VEGF in the NALF at 6 h after OVA 
challenge was significantly increased compared to saline-treated 
animals (p = 0.0246). Olopatadine at 10 mg/kg/day significantly 
inhibited the increased levels of VEGF by 98.5% (p = 0.0193). 
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Fig. 3. Nasal skin temperature change after the last nasal ovalbumin (OVA) challenge. Maximum (A) and mean (B) temperature change. Olopatadine and 
prednisolone were orally administered 1 h before the OVA challenge. The nasal skin temperature was measured at 0.25, 0.5, 1, 2, 3, 4 and 6 h after the 
OVA challenge. ✕: saline, ●: OVA challenge, □: olopatadine, ■: prednisolone. Each point represents the mean ± SE of 6 rats. 
†p < 0.05, 
††p < 0.01, 
†††p < 
0.001: significantly different from the OVA challenged group.
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Fig. 4. Effects of olopatadine and prednisolone on the number of 
sneezing induced by the ovalbumin (OVA) challenge. Olopatadine and 
prednisolone were orally administered before the OVA challenge. The 
number of sneezing was measured for 10 min. Each column represents 
the mean ± SE of 7 rats. Saline: physiological saline challenge, OVA: OVA 
challenged control. †††p < 0.001: significantly different from the OVA 
challenged group (Student’s t-test). 
‡‡‡p < 0.001: significantly different 
from the OVA challenged group (Aspin-Welch test). 
**p < 0.01, 
***p < 0.001: 
significantly different from the OVA challenged group (Dunnett test). 
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Prednisolone significantly inhibited the increased levels of VEGF by 
87.4% (p = 0.0301).
DISCUSSION
In OVA-sensitized rats, the number of sneezing episodes 
increases and the nasal skin temperature rises were provoked after 
OVA challenge. Olopatadine reduced the increased frequency of 
sneezing and the nasal temperature rise. The levels of NGF and 
VEGF in NALF also were increased by OVA challenge. Olopatadine 
inhibited the increased NGF and VEGF production.
The efficacy of antihistamines on rhinitis was compared 
by measuring nasal symptoms and rhinomanometry, which 
olopatadine is considered effective for symptoms such as sneezing, 
rhinorrhea and nasal obstruction [3, 17-19]. In clinical study, the 
antihistaminic activity of levocetirizine and fexofenadine was 
assessed using facial thermography during nasal provocation tests 
with histamine and allergen [6]. In this study, olopatadine reduced 
the sneezing and the risen nasal temperature in the OVA-induced 
allergic rhinitis model. Therefore the assay using thermography 
also could become a useful clinical indicator in animal model.
In this study, skin minimum temperature of the nose area did 
not changed, but skin maximum and mean temperature rise were 
observed during 0.25-3 h, and those rises were observed again at 
6 h after OVA challenge. The main symptoms of AR are observed 
in the early phase and the late phase of the disease. The early 
phase response, characterized by sneezing, rhinorrhea and nasal 
congestion, occurs within a few minutes of antigen exposure 
and subsides after 30-90 min. In contrast, the late phase reaction, 
characterized mainly by nasal congestion, begins around 4-8 
h after the early phase response [20]. Olopatadine significantly 
inhibited the decrease in the nasal cavity volume at the early 
phase and the late phase after the antigen challenge [21]. 
Nasal congestion may be due to the increased nasal blood flow 
and nasal temperature increase may be involved in blood flow; 
blood flow is thought to cause the swelling of nasal mucosa. The 
swelling of nasal mucosa by antigen are considered a direct effect 
on the nasal mucosa vasculature of chemical mediators such as 
histamine, cysteinyl leukotrienes and PAF [22-24]. It is also reported 
that capsaicin sensitive sensory nerve reflexes were related to 
nasal blockage [25]. It has been shown that olopatadine inhibits 
the release and the action of histamine, the release of peptide 
leukotrienes [26], the production of PAF and leukotriene B4, and 
the release of neuropeptides [27]. Accordingly, the efficacy of 
olopatadine on nasal temperature increase is likely to be based on 
these actions; that is, inhibitory actions on the release of histamine, 
peptide leukotrienes and neuropeptides, and on the production of 
PAF as well as based on the antagonistic actions on histamine. 
VEGF is produced from mast cell and is involved in type Ⅰ allergy 
[28].  Therefore, VEGF is thought to contribute to the swelling 
of nasal mucosa by the increased vascular permeability in the 
early phase of AR. It is suggested that olopatadine is suppressing 
the swelling of nasal mucosa by the inhibitory effect of LTs [21]. 
Relationship between blood flow, swelling of nasal mucosa and 
nasal temperature in this model is not clear. The inhibitory effect 
on nasal temperature of olopatadine was suggested that it is 
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Fig. 5. Effects of olopatadine and prednisolone on the production of nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) in the 
nasal lavage fluids (NALF) induced by the ovalbumin (OVA) challenge. NGF (A) and VEGF (B) levels in the NALF were measured 6 h after OVA challenge. 
Each column represents the mean ± SE of 6-7 rats. *p < 0.05: significantly different from the OVA challenged group (Dunnett test). 
†p < 0.05: significantly 
different from the OVA challenged group (Student’s t-test). 
‡p < 0.05: significantly different from the OVA challenged group (Aspin-Welch test). 
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involved H1 antagonistic effects and the inhibition of LTs release in 
addition to the inhibition of increased histamine and VEGF.
NGF increases the sensitivity to sneeze reflex and makes an 
increase in nasal rhinorrhea and plasma leakage by sensory nerve 
stimulation [29]. The amount of NGF in NALF of patients with AR 
is increasing compared to healthy volunteers, it were additional 
increased by the antigenic exposure [30]. Neuropeptides positive 
nerve fibers are increased in nasal mucosa of patients with AR. 
Neuropeptides may exacerbate further exposure to antigen 
reaction by encouraging the extension of nerve fibers. In this 
study, olopatadine inhibited the NGF production. These results 
suggest that the suppression of the increase in NGF might partially 
be involved in the improvement of allergy-like behavior and nasal 
temperature increase.
Olopatadine reduced the risen nasal temperature in the 
OVA-induced allergic rhinitis model. Therefore the assay using 
thermography could become a useful clinical indicator in animal 
model. More detailed studies will be required to ascertain the 
precise mechanism of action of olopatadine on nasal blockage. 
These results suggest that the suppression of the increased NGF 
and VEGF levels might partially be involved in the improvement of 
allergy-like behavior (sneezing and nasal skin temperature rise) by 
the treatment of olopatadine.
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